A Phase II Study of Atezolizumab with Bevacizumab for Patients with PD-L1 High Expression Non-Small Cell Non-Squamous Cell Lung Cancer (WJOG10718L Investigator-Initiated Clinical Trial)
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2018
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms At Be Study
- 08 Aug 2018 Last checked against Japan Pharmaceutical Information Center - Clinical Trials Information record.
- 06 Aug 2018 Status changed from not yet recruiting to recruiting.
- 23 Jul 2018 New trial record